Analysts predict that Theravance Biopharma, Inc. (NASDAQ:TBPH) will report $4.06 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Theravance Biopharma’s earnings, with estimates ranging from $3.11 million to $5.00 million. Theravance Biopharma reported sales of $5.47 million in the same quarter last year, which indicates a negative year over year growth rate of 25.8%. The business is expected to announce its next quarterly earnings results on Monday, August 14th.

According to Zacks, analysts expect that Theravance Biopharma will report full-year sales of $4.06 million for the current fiscal year, with estimates ranging from $12.57 million to $21.40 million. For the next year, analysts forecast that the company will post sales of $40.74 million per share, with estimates ranging from $22.97 million to $58.50 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for Theravance Biopharma.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.14) by $0.13. Theravance Biopharma had a negative return on equity of 67.69% and a negative net margin of 641.67%. The company had revenue of $3.09 million for the quarter, compared to the consensus estimate of $5.07 million.

A number of research analysts have issued reports on the company. Cantor Fitzgerald set a $55.00 price objective on Theravance Biopharma and gave the company a “buy” rating in a research note on Wednesday. BidaskClub downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Sunday, July 16th. ValuEngine upgraded Theravance Biopharma from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Leerink Swann set a $47.00 price objective on Theravance Biopharma and gave the company a “buy” rating in a research note on Wednesday, May 10th. Finally, Needham & Company LLC upped their price objective on Theravance Biopharma from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, May 11th. Three analysts have rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company. Theravance Biopharma currently has an average rating of “Hold” and an average target price of $41.13.

Theravance Biopharma (NASDAQ TBPH) opened at 36.37 on Friday. The firm’s 50-day moving average is $39.20 and its 200-day moving average is $35.62. Theravance Biopharma has a 52-week low of $22.13 and a 52-week high of $43.44. The company’s market capitalization is $1.94 billion.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Woodford Investment Management Ltd increased its position in shares of Theravance Biopharma by 1.9% in the first quarter. Woodford Investment Management Ltd now owns 10,705,108 shares of the biopharmaceutical company’s stock valued at $393,948,000 after buying an additional 197,500 shares in the last quarter. BlackRock Inc. increased its position in shares of Theravance Biopharma by 117,412.4% in the first quarter. BlackRock Inc. now owns 3,512,445 shares of the biopharmaceutical company’s stock valued at $129,326,000 after buying an additional 3,509,456 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Theravance Biopharma by 4.2% in the first quarter. Vanguard Group Inc. now owns 3,080,296 shares of the biopharmaceutical company’s stock valued at $113,417,000 after buying an additional 125,223 shares in the last quarter. State Street Corp increased its position in shares of Theravance Biopharma by 2.3% in the first quarter. State Street Corp now owns 870,254 shares of the biopharmaceutical company’s stock valued at $32,042,000 after buying an additional 19,230 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Theravance Biopharma during the fourth quarter valued at approximately $27,631,000. Institutional investors own 84.30% of the company’s stock.

WARNING: This report was published by American Banking News and is owned by of American Banking News. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.americanbankingnews.com/2017/07/22/brokerages-anticipate-theravance-biopharma-inc-tbph-will-announce-quarterly-sales-of-4-06-million.html.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Get a free copy of the Zacks research report on Theravance Biopharma (TBPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.